Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jawassociated clinical characteristics

  1. Leticia Bagán Debón 1
  2. Yolanda Jiménez Soriano 2
  3. Manuel Leopoldo Rodado 3
  4. Judith Murillo Cortés 4
  5. José Vicente Bagán Sebastián 5
  1. 1 Associate Professor of Oral Medicine. Universidad Europea de Valencia
  2. 2 Professor of oral manifestations of systemic diseases. Valencia University
  3. 3 Oral and Maxillofacial Surgeon. Consultant. University General Hospital
  4. 4 University General Hospital, Valencia, Spain
  5. 5 Professor of Oral Medicine, Valencia University. Head Service of Stomatology and Maxillofacial Surgery, University General Hospital. Fundación para la investigación del Hospital General Universitario de Valencia, Spain
Mostrar afiliaciones +
Revista:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Año de publicación: 2017

Volumen: 22

Número: 5

Páginas: 9

Tipo: Artículo

DOI: 10.4317/MEDORAL.22133 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Resumen

The main objective of our study was to identify oral symptoms and signs most likely to be associated with the exposure of necrotic bone in bisphosphonate-related osteonecrosis of the jaw (BRONJ). The study group consisted of 183 patients with BRONJ. We recorded data on the underlying disease, bisphosphonate used, location of osteonecrosis, symptoms, pain, fistula development, suppuration, infection, exposed necrotic bone, and BRONJ stage. The mean age of the patients was 68.22 ± 12.19 years. The sample included 118 (64.5%) women. Breast cancer and multiple myeloma were the most common underlying diseases, and 50 patients received oral bisphosphonates for osteoporosis. Dental extractions (69.4%) and mandibular location (74.3%) predominated. The only two variables influencing the possibility of necrotic bone exposure were intravenous bisphosphonate administration and the presence of an intraoral fistula (p >0.05). Intravenous bisphosphonate use and intraoral fistula presence were associated with a major predisposition to bone exposure in patients with BRONJ.

Referencias bibliográficas

  • Marx, RE. (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 61. 1115
  • Bagan, JV, Murillo, J, Jimenez, Y, Poveda, R, Milian, MA, Sanchis, JM. (2005). Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 34. 120
  • Ruggiero, SL, Fantasia, J, Carlson, E. (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 102. 433
  • Boonyapakorn, T, Schirmer, I, Reichart, PA, Sturm, I, Massenkeil, G. (2008). Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44. 857
  • Lazarovici, TS, Yahalom, R, Taicher, S, Elad, S, Hardan, I, Yarom, N. (2009). Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg. 67. 850
  • Bagan, J, Sheth, CC, Soria, JM, Margaix, M, Bagan, L. (2013). Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. J Oral Pathol Med. 42. 405
  • Vescovi, P, Merigo, E, Meleti, M, Manfredi, M, Guidotti, R, Nammour, S. (2012). Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 41. 214
  • Vescovi, P, Meleti, M, Merigo, E, Manfredi, M, Fornaini, C, Guidotti, R. (2013). Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 18. 680
  • Japanese Allied Committee on Osteonecrosis of the, Jaw, Yoneda, T, Hagino, H, Sugimoto, T, Ohta, H, Takahashi, S. (2017). Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 35. 6-19
  • Fung, P, Bedogni, G, Bedogni, A, Petrie, A, Porter, S, Campisi, G. (2017). Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis. 23. 477-483
  • Ruggiero, SL, Dodson, TB, Fantasia, J, Goodday, R, Aghaloo, T, Mehrotra, B. (2014). American Association of Oral and Maxillofacial Surgeons position paper onmedication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 72. 1938
  • Bagan, JV, Jimenez, Y, Murillo, J, Hernandez, S, Poveda, R, Sanchis, JM. (2006). Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 42. 327
  • Lodi, G, Sardella, A, Salis, A, Demarosi, F, Tarozzi, M, Carrassi, A. (2010). Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg. 68. 107
  • Malden, N, Beltes, C, Lopes, V. (2009). Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J. 206. 93
  • Yamazaki, T, Yamori, M, Ishizaki, T, Asai, K, Goto, K, Takahashi, K. (2012). Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 41. 1397
  • Nicolatou-Galitis, O, Papadopoulou, E, Sarri, T, Boziari, P, Karayianni, A, Kyrtsonis, MC. (2011). Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112. 195-202
  • Fedele, S, Porter, SR, D'Aiuto, F, Aljohani, S, Vescovi, P, Manfredi, M. (2010). Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 123. 1060
  • Bedogni, A, Fedele, S, Bedogni, G, Scoletta, M, Favia, G, Colella, G. (2014). Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 52. 603
  • Black, DM, Reid, IR, Boonen, S. (2012). The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 27. 243
  • Stumpe, MR, Chandra, RK, Yunus, F. (2009). Incidence and risk factors of bisphosphonate associated osteonecrosis of the jaws. Head Neck. 31. 202
  • Saad, F, Brown, JE, Van Poznak, C. (2012). Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 23. 1341
  • Khan, AA, Morrison, A, Hanley, DA, Felsenberg, D, McCauley, LK, O'Ryan, F. (2015). Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 30. 3-23
  • Kos, M. (2014). Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. Arch Med Sci. 10. 117
  • Kos, M. (2015). Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 11. 319
  • Marx, RE, Cillo, JE Jr, Ulloa, JJ. (2007). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 65. 2397
  • Ruggiero, SL, Dodson, TB, Assael, LA, Landesberg, R, Marx, RE, Mehrotra, B. (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 35. 119
Fuente de los datos: Dialnet